Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 5, 2024
Discovery & Translation
New frontiers in extracellular protein degradation
Six papers detail improved ways to degrade cell-surface cancer proteins through the lysosome
BioCentury | Sep 3, 2024
Discovery & Translation
Neurology’s human data revolution
Back to School 2024 looks at how neuroscience companies are reducing to practice the concept of human-first discovery
BioCentury | Jun 21, 2024
Product Development
Rare Disease Spotlight: Rare form of dementia a gateway indication for PGRN?
Half a dozen programs aim to boost PGRN expression in the CNS. They are targeting FTD-GRN as a proving ground
BioCentury | Jun 18, 2024
Product Development
Tumor cell surface targets off the beaten path
Beyond the headlines at ASCO and AACR were a set of less traveled cancer targets, including neuronal proteins hijacked by solid tumors
BioCentury | Feb 28, 2024
Emerging Company Profile
Vesper Bio: a sortilin-targeting pill to treat neurological disease
Lundbeckfonden-backed start-up believes at-home oral therapy would offer benefits over injectables for genetically defined patients with dementia
BioCentury | Jul 7, 2021
Finance
Biotechs hit 3Q with coolers full of cash; plus Distillery on Tap: a BioCentury podcast
The slowdown in biopharma financings and M&A has provided some buysiders a welcome relief from the breakneck pace of the past year and a half, and with many companies’ coffers full, the
BioCentury | Jul 2, 2021
Deals
Alector’s pair of sortilin mAbs drive GSK’s ‘flagship’ neurodegeneration deal
The biotech gets $700M up front to fuel clinical testing
BioCentury | Apr 8, 2021
Product Development
Next-generation drug conjugates in the spotlight at AACR
New ADC targets, structures and functionalities fill AACR21 abstracts
BioCentury | Nov 8, 2019
Emerging Company Profile
Arkuda emerges from Atlas with genetic dementia program
Atlas-founded Arkuda debuts with genetically-defined frontotemporal dementia therapy, $44M A round
BioCentury | Jul 20, 2019
Clinical News
July 19 Clinical Quick Takes: Polyphor closes Phase III murepavadin trials; plus Takeda and Alector
Items per page:
1 - 10 of 23